A hand holds up a tamper-safe orange bottle filled with oblong white pills against a red-tinted background of Chinese yuan. As China’s biopharmaceutical industry churns out more innovative molecules, ...

XBI biotech ETF surged 65% as M&A heats up, but 2026 brings headwinds and tougher gains. Click here for a detailed analysis.

The biotech sector is entering 2026 with a positive outlook, characterized by reasonable valuations, robust oncology momentum and supportive policy tailwinds. This combination is setting the stage for ...